Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3042]
News [6141]
Articles [120]
Editorials [18]
Conferences [181]
elearning [32]
ASCO 2014: Less frequent zoledronic acid is safe, and has comparable efficacy for women with breast cancer and bone metastases, compared to the standard monthly treatment
ASCO 2014: Less frequent zoledronic acid is safe, and has comparable efficacy for women with breast cancer and...
ASCO 2014: Discontinuing statins near the end of life is safe, improves patient quality of life
ASCO 2014: Discontinuing statins near the end of life is safe, improves patient quality of life
Research in several cancers reveals promising treatment strategies, new insights on screening, and obesity-cancer link
Research in several cancers reveals promising treatment strategies, new insights on screening, and obesity-cancer...
Delaying androgen deprivation therapy may be safe for men with prostate cancer relapse detected by PSA testing
Delaying androgen deprivation therapy may be safe for men with prostate cancer relapse detected by PSA testing
PLX3397 may provide a new treatment option for patients with recurrent pigmented villonodular synovitis
PLX3397 may provide a new treatment option for patients with recurrent pigmented villonodular synovitis
Obesity substantially increases breast cancer mortality only in women with pre-menopausal ER disease
Obesity substantially increases breast cancer mortality only in women with pre-menopausal ER disease
NICE rejects use of abiraterone for advanced prostate cancer before chemo
NICE rejects use of abiraterone for advanced prostate cancer before chemo
IMPAKT: Molecular subtype of a breast cancer relapse influences patient post-relapse survival
IMPAKT: Molecular subtype of a breast cancer relapse influences patient post-relapse survival
IMPAKT: Therapeutic effect and markers of response of palbociclib in HER2-positive breast cancer models
IMPAKT: Therapeutic effect and markers of response of palbociclib in HER2-positive breast cancer models
IMPAKT: Enzalutamide with or without an aromatase inhibitor for advanced breast cancer
IMPAKT: Enzalutamide with or without an aromatase inhibitor for advanced breast cancer

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation